ALFA Finder| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 1063.1 | 1003.4 | 760.8 |
| Other income | 29.0 | 10.8 | 22.1 |
| Total income | 1092.1 | 1014.2 | 782.9 |
| Profit before exceptional items & tax | 152.7 | 125.4 | 152.1 |
| Exceptional items | 0.0 | -20.3 | 0.0 |
| Profit before tax | 152.7 | 105.1 | 152.1 |
| Net profit | 116.2 | 79.7 | 116.4 |
| Operating margin | 14.0% | 10.4% | 19.4% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -0.20% |
|---|---|
| Net profit, quarter on quarter | +45.80% |
| Revenue, year on year | +39.70% |
| Operating profit, year on year | -7.50% |
| Operating profit, quarter on quarter | +26.60% |
BSE results filing, NSE: INDGN. Figures extracted from the filing.
Indegene Ltd: key numbers
- Share price
- ₹623.85
- Market cap
- ₹15,030 Cr
- Revenue (annual)
- ₹3,510 Cr
- Net profit (annual)
- ₹401.1 Cr
- P/E (TTM)
- 36.6×Sector 54.5×
- Promoter holding
- 0.00%+0.00% QoQ
- FII holding
- 12.40%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Indegene Ltd
All →Indegene Earnings Call Transcript: Key Takeaways
Strong top-line growth driven by pharma digital transformation, but near-term margins are compressed by annual wage hikes and mutual fund mark-downs.
Indegene Management Change
Indegene's Company Secretary and Compliance Officer Srishti Ramesh Kaushik resigned, effective 02-Dec-2026. The resignation cites future career advancement.
Indegene Employee Stock Options
Indegene Limited allotted 52,194 equity shares under its ESOP schemes, raising paid-up capital to Rs.48.21 Crore. No cash fund raise is involved, so no event value applies.
Indegene Investor Presentation: Key Takeaways
Q2 FY27 revenue INR 11,223M (+39.5% YoY, +5.6% QoQ), EBITDA margin 16.7%, PAT INR 1,123M (+10% YoY). BioPharm integration ahead of plan.
Indegene Results Update
Indegene reported Q2 FY27 revenue of ₹11,223M, up 39.5% YoY, with PAT of ₹1,123M. H1 USD revenue growth reached a four-year high of 27.0%.
Indegene Q2 FY27 Results: Net Profit ₹112.3 Cr, Up 10.0% YoY
Indegene Ltd reported revenue from operations of ₹1,122 Cr (+39.6% YoY) and net profit of ₹112.3 Cr (+10.0% YoY) for Q2 FY27.
- Key figure
- Net profit ₹112.3 Cr · +10.0% YoY